An Overview of the Ongoing SIERRA Trial in Relapsed/Refractory AML
Rajneesh Nath, MD, director, stem cell transplant and acute leukemia program, Banner MD Anderson Cancer Center, discusses the ongoing phase III SIERRA trial, which is evaluating targeted conditioning of Iomab-B prior to allogeneic hematopoietic cell transplantation versus conventional care in patients with relapsed/refractory acute myeloid leukemia (AML).<br />
Rajneesh Nath, MD, director, stem cell transplant and AML program, Banner MD Anderson Cancer Center, discusses the ongoing phase III SIERRA trial, which is evaluating targeted conditioning of Iomab-B prior to allogeneic hematopoietic cell transplantation versus conventional care in patients with relapsed/refractory acute myeloid leukemia (AML).
This trial focuses on elderly patients who have relapsed or refractory AML that is not responding to standard therapy, Nath explains. Patients who are elderly, as well as patients who have active disease at the time of transplant, generally do not do well. Both of these patient groups will be included on this trial.
